KARBF: AI 评分 46/100 — AI 分析 (4月 2026)

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products. The company focuses on the Nordic region and Europe, with sales in approximately 90 countries.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products. The company focuses on the Nordic region and Europe, with sales in approximately 90 countries.

Karo Pharma AB (publ) develops and markets a diverse portfolio of prescription and over-the-counter products, focusing on skin health, intimate health, and pain relief, primarily in Europe and the Nordic region. The company distributes its products through direct sales and a network of distributors, including online channels.

KARBF是做什么的？

Karo Pharma AB (publ), founded in 1987 and headquartered in Stockholm, Sweden, is a pharmaceutical company focused on developing and marketing prescription drugs and over-the-counter (OTC) products. Originally named Karo Bio AB (publ), the company changed its name in March 2016 to Karo Pharma AB (publ). The company's product portfolio includes skin health products marketed under brands like Remescar, Locobase, Decubal, and indy beauty. It also offers intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brands, and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. Additionally, Karo Pharma provides pain, cough, and cold remedies under brands such as Paracet, Ibux, Mollipect, and Viruseptin. The company also markets prescription drugs, including Burinex, Centyl, Kaleorid, and Lithionit, alongside wellness products like nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare. Karo Pharma distributes its products in approximately 90 countries, primarily in Europe and the Nordic region, through a combination of direct sales organizations, a network of distributors, and online channels. This diversified product range and extensive distribution network position Karo Pharma as a key player in the European and Nordic pharmaceutical markets.

KARBF的投资论点是什么？

Karo Pharma presents a compelling investment case based on its diversified product portfolio and established presence in the European and Nordic pharmaceutical markets. With a market capitalization of $1.52 billion, the company benefits from a broad range of prescription and OTC products targeting various health needs. Growth catalysts include expanding its online sales channels and further penetrating existing markets. Key value drivers include consistent revenue from established brands and potential for new product launches. However, the may be worth researching risks associated with regulatory changes and competition from larger pharmaceutical companies. The company's ability to maintain market share and innovate new products will be critical for sustained growth.

KARBF在哪个行业运营？

Karo Pharma operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The market is driven by an aging population, increasing healthcare awareness, and the rising prevalence of chronic diseases. Karo Pharma competes with both large multinational corporations and smaller regional players. Key trends include the growing demand for OTC products, the increasing importance of online sales channels, and the need for continuous product innovation to maintain market share. The company's focus on the European and Nordic markets positions it well to capitalize on regional growth opportunities.

Drug Manufacturers - Specialty & Generic

Healthcare

KARBF有哪些增长机遇？

Expansion of Online Sales Channels: Karo Pharma can significantly boost revenue by expanding its online sales channels. The e-commerce market for pharmaceuticals is growing rapidly, offering direct access to consumers and reducing reliance on traditional distribution networks. Investing in digital marketing and e-commerce infrastructure can increase market reach and improve customer engagement. This strategy aligns with the increasing trend of online healthcare purchases and can drive substantial growth in the coming years. The global e-pharmacy market is projected to reach $177.79 billion by 2026.
Penetration of Existing Markets: Karo Pharma has the opportunity to deepen its penetration in existing markets, particularly in Europe and the Nordic region. By increasing marketing efforts, expanding distribution partnerships, and launching new products tailored to local needs, the company can capture a larger share of these established markets. This strategy leverages existing infrastructure and brand recognition, reducing the risks associated with entering new geographic regions. Focused market penetration can lead to sustainable revenue growth and improved profitability.
Strategic Acquisitions: Karo Pharma can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring smaller pharmaceutical companies with complementary products or established presence in new markets can accelerate growth and diversify revenue streams. Careful due diligence and integration are crucial for successful acquisitions. This strategy can provide access to new technologies, intellectual property, and distribution networks, enhancing Karo Pharma's competitive position and long-term growth prospects.
New Product Development: Investing in research and development to create innovative new products is essential for sustained growth. Karo Pharma can focus on developing novel formulations, line extensions, and products addressing unmet medical needs. This strategy requires a strong R&D pipeline and a commitment to innovation. Successful new product launches can drive revenue growth, improve brand image, and enhance Karo Pharma's competitive advantage in the pharmaceutical market. Focus on areas like dermatology and women's health could yield high-growth opportunities.
Partnerships and Collaborations: Karo Pharma can leverage partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to expand its capabilities and market reach. Collaborations can provide access to new technologies, expertise, and distribution channels. Strategic partnerships can also reduce the risks and costs associated with developing and commercializing new products. This strategy can accelerate innovation, improve market access, and enhance Karo Pharma's overall competitiveness in the pharmaceutical industry.

Karo Pharma operates in approximately 90 countries, demonstrating a broad international presence.
The company's product portfolio includes both prescription and over-the-counter drugs, providing diversified revenue streams.
Karo Pharma focuses on the European and Nordic markets, leveraging established distribution networks.
The company's key product categories include skin health, intimate health, and pain relief, addressing significant consumer needs.
Karo Pharma's market capitalization stands at $1.52 billion, reflecting its established position in the pharmaceutical industry.

KARBF提供哪些产品和服务？

Develops and markets prescription drugs.
Offers over-the-counter (OTC) products for pharmacies and retail sectors.
Provides skin health products under various brand names.
Markets intimate health products.
Offers foot health products.
Provides pain, cough, and cold remedies.
Sells wellness products.

KARBF如何赚钱？

Develops and manufactures pharmaceutical products.
Markets products through direct sales organizations and a network of distributors.
Sells products online.
Focuses on the European and Nordic markets.

Pharmacies
Retail sector
Consumers in Europe and the Nordic region
Hospitals and healthcare providers

Established brand recognition in the Nordic region and Europe.
Diversified product portfolio across multiple therapeutic areas.
Extensive distribution network.
Strong relationships with pharmacies and retailers.

什么因素可能推动KARBF股价上涨？

Upcoming: Potential for new product launches in the skin health and intimate health categories.
Ongoing: Expansion of online sales channels to reach a broader customer base.
Ongoing: Strategic partnerships and collaborations to enhance product development and market access.

KARBF的主要风险是什么？

Potential: Increased competition from generic drug manufacturers.
Potential: Changes in healthcare regulations affecting pricing and market access.
Ongoing: Dependence on key brands and product lines.
Potential: Product liability claims and recalls.

KARBF的核心优势是什么？

Diversified product portfolio.
Strong presence in the Nordic region and Europe.
Established distribution network.
Experienced management team.

KARBF的劣势是什么？

Reliance on specific geographic markets.
Exposure to regulatory changes.
Competition from larger pharmaceutical companies.
Dependence on key brands.

KARBF有哪些机遇？

Expansion into new geographic markets.
Development of innovative new products.
Strategic acquisitions.
Increased online sales.

KARBF面临哪些威胁？

Generic competition.
Pricing pressures.
Changes in healthcare regulations.
Product liability claims.

KARBF的竞争对手是谁？

Bayer AG — Global pharmaceutical and life sciences company. — (BIESF)
BioNTech SE — Focuses on immunotherapies and vaccines. — (BITGF)
Sanofi — Diversified healthcare company. — (CMPUY)
Sanofi — Global pharmaceutical company with a broad range of products. — (CMPVF)
Coloplast A/S — Develops and markets products for intimate healthcare. — (CSWYF)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Christoffer Lorenzen
Headquarters: Stockholm, SE
Employees: 225
Founded: 2013

AI Insight

AI analysis pending for KARBF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Karo Pharma AB (publ) do?

Karo Pharma AB (publ) is a pharmaceutical company that develops and markets a range of prescription and over-the-counter (OTC) products. Its portfolio includes skin health, intimate health, foot health, and pain relief products, sold under various brand names. The company operates primarily in Europe and the Nordic region, distributing its products through direct sales, a network of distributors, and online channels. Karo Pharma aims to address diverse consumer health needs with its broad product offerings.

What do analysts say about KARBF stock?

AI analysis is pending for KARBF. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is currently unavailable. Investors should monitor for future updates and conduct their own independent research to assess the potential risks and rewards associated with investing in Karo Pharma AB (publ). Further analysis will provide insights into the company's financial performance and market outlook.

What are the main risks for KARBF?

Karo Pharma faces several risks, including competition from generic drug manufacturers, which could erode market share and pricing power. Changes in healthcare regulations could also impact the company's ability to market and sell its products. Additionally, the company is dependent on key brands and product lines, making it vulnerable to market shifts and consumer preferences. Product liability claims and recalls also pose a risk to Karo Pharma's reputation and financial performance. These factors should be carefully considered by investors.

How does Karo Pharma AB (publ) navigate regulatory approval processes?

Information regarding Karo Pharma AB (publ)'s specific FDA/EMA regulatory track record, pending approvals, and compliance strategy is not available in the provided data. However, as a pharmaceutical company, Karo Pharma must adhere to stringent regulatory requirements in each of the markets it operates in. Successfully navigating these processes is crucial for bringing new products to market and maintaining compliance with existing regulations. Investors should monitor the company's regulatory filings and announcements for updates on this front.

How does Karo Pharma AB (publ) manage patent expiration risks?

Information regarding Karo Pharma AB (publ)'s patent cliff exposure, biosimilar competition, and lifecycle management strategies is not available in the provided data. However, as a pharmaceutical company, Karo Pharma faces the risk of patent expirations on its branded products, which could lead to increased competition from generic alternatives. Effective lifecycle management strategies, such as developing new formulations or indications for existing products, are crucial for mitigating this risk. Investors should monitor the company's patent portfolio and pipeline for updates on this front.